1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Minor Use Minor Species Development of Drugs (R01) (PAR-24-216) is sponsored by U.S. Food and Drug Administration (FDA) / National Institutes of Health (NIH). This grant supports the development and potential approval or conditional approval of new animal drugs intended to treat uncommon diseases (minor uses) in major species or to treat minor species. It covers routine safety, effectiveness, manufacturing, and toxicology studies.
Get alerted about grants like this
Get emailed when new opportunities from “U.S. Food and Drug Administration (FDA) / National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Animal drug sponsors with Designated Minor Use and Minor Species (MUMS) animal drugs or their research partners are eligible. Applicants must meet other FDA eligibility requirements. Confirm the full requirements in the official notice before applying.
The current listing shows up to $250,000 per year for up to 2-3 years (up to $500,000 - $750,000 total). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Minor Use Minor Species Development of Drugs (R01) (PAR-24-216) are due July 24, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Minor Use Minor Species Development of Drugs (R01) (PAR-24-216) is funded by U.S. Food and Drug Administration (FDA) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional) RFA-OD-25-008 is sponsored by U.S. Food and Drug Administration (FDA) / National Institutes of Health (NIH). This program supports new biomedical, behavioral, and social science investigators in the early stages of establishing independent careers in tobacco regulatory research.
Small Business Innovation Research (SBIR) Grant Program for Medical Device Innovators is sponsored by U.S. Food and Drug Administration (FDA) / National Institutes of Health (NIH). This program encourages domestic small businesses to engage in research and development of innovative medical devices with the potential for commercialization. CDRH's interest areas are announced annually in the SBIR Omnibus/Parent Grant Solicitation.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
This initiative will stimulate and support innovative research by small business concerns that may lead to the development of novel technologies for the early diagnosis, monitoring and treatment of micro and macro vascular complications of diabetes which are associated with significant morbidity and mortality of the disease and high costs to the health care system. Funding Opportunity Number: PA-14-058. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL.
NIH has awarded 74% fewer new grants than its 2021-2024 average and is roughly $1 billion behind its normal timeline, but the FY2026 money still has to go out the door before the fiscal year ends. Here is why a year-end obligation cliff is coming, who is positioned to catch it, and how applicants should prepare for a compressed Q4 award rush.
Read articleNew NIH awards have fallen 34% in 2026, NSF is running months behind, and a proposed OMB rule would let political appointees terminate grants mid-stream. The funding environment for academic research has structurally changed. Here is a clear-eyed diversification strategy for PIs, research offices, and institutions that cannot wait for the political fight to resolve.
Read articleUSDA's FY2026 GusNIP Produce Prescription Program will make roughly 12 awards of up to $500,000 over three years — with no matching requirement — to nonprofits and government agencies that partner with healthcare providers to prescribe fresh fruits and vegetables. Here is who is eligible, why the mandatory clinical partner is the whole game, how the evidence base got strong enough to matter, and how to build a July 16 application.
Read article